These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

578 related items for PubMed ID: 29065396

  • 41. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
    Lv JT, Yang ZG, Guang YH, Lin ZS, Xiao XX, Liu D, Shi M, Wang WS.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
    [Abstract] [Full Text] [Related]

  • 42. Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.
    Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, Valent P.
    Leuk Lymphoma; 2006 Feb; 47(2):207-22. PubMed ID: 16321850
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.
    Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.
    Oncotarget; 2012 Dec; 3(12):1588-99. PubMed ID: 23249862
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F, Al-Mudallal SS.
    Cardiovasc Hematol Disord Drug Targets; 2020 Dec; 20(2):145-151. PubMed ID: 31438833
    [Abstract] [Full Text] [Related]

  • 47. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.
    Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.
    PLoS One; 2014 Dec; 9(9):e107587. PubMed ID: 25244440
    [Abstract] [Full Text] [Related]

  • 48. Survival outcomes of CD34+CD38-LSCs and their expression of CD123 in adult AML patients.
    Zahran AM, Aly SS, Rayan A, El-Badawy O, Fattah MA, Ali AM, ElBadre HM, Hetta HF.
    Oncotarget; 2018 Sep 25; 9(75):34056-34065. PubMed ID: 30344921
    [Abstract] [Full Text] [Related]

  • 49. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, Reilly RM.
    J Nucl Med; 2011 Sep 25; 52(9):1465-73. PubMed ID: 21816968
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L, Jorgensen JL, Brooks C, Shi C, Zhang Q, Nogueras González GM, Cavazos A, Pan R, Mu H, Wang SA, Zhou J, Ai-Atrash G, Ciurea SO, Rettig M, DiPersio JF, Cortes J, Huang X, Kantarjian HM, Andreeff M, Ravandi F, Konopleva M.
    Clin Cancer Res; 2017 Jul 01; 23(13):3385-3395. PubMed ID: 28096272
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T, Babusíková O.
    Neoplasma; 2006 Jul 01; 53(6):500-6. PubMed ID: 17167719
    [Abstract] [Full Text] [Related]

  • 58. Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.
    Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.
    PLoS One; 2013 Jul 01; 8(11):e78897. PubMed ID: 24244383
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
    Du W, Li XE, Sipple J, Pang Q.
    Blood; 2011 Apr 21; 117(16):4243-52. PubMed ID: 21330473
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.